Alexion pexelizumab fails second PRIMO study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alexion's terminal complement inhibitor pexelizumab fails to show statistical significance in the firm's second coronary artery bypass graft trial, PRIMO-CABG2. Alexion is assessing the implications of the results on its APEX-AMI study of the biologic in acute myocardial infarction. When pexelizumab failed the first PRIMO (Pexelizumab for Reduction in Infarction & Mortality) study in August 2003, Alexion said the results could be used to support an AMI indication (Pharmaceutical Approvals Monthly September 2003, p. 21). The APEX study has enrolled 3,000 patients, according to the firm...